Processa Pharmaceuticals, Inc.
corporate_fare Company Profile
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for PCSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 10/10, with 9 rated 8 or above. Recent SEC coverage for PCSA spans 10-Q, 8-K, PRE 14A, S-3.
Recent high-impact activity:
- Processa 10-Q: $180.2M Cash but Going Concern Doubt Tied to Series A Conversion
- Processa Letter Puts As-Converted Share Count at 309.3M vs 2.8M Trading
- Processa Names Gujrathi Executive Chair, Adds Generian FcRn Program, Extends Runway to 2H 2029
- FDA Clears IND for Processa's VT-7208 Phase 2 CSU Trial
- Processa Seeks Reverse Split Approval to Meet Nasdaq $4.00 Listing Requirement
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 26,138 shares in PCSA as of the October 30, 2026 settlement, a 43.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 30.6% of PCSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PCSA, detected from its recent SEC filings.
306.6M Shares Registered for Resale · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →